Publications by authors named "Joon Ho Yi"
Article Synopsis
- A prognostic model was developed to predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving gefitinib therapy, based on clinical parameters.
- Among 316 analyzed patients, multiple poor prognostic factors were identified, including performance status, metastasis presence, and serum markers.
- The model stratified patients into four prognosis groups, with median OS ranging from 18.0 months for the good prognosis group to just 1.3 months for the very poor prognosis group, highlighting its potential clinical utility.
